Every­one wants an ADC: GSK pays $85M up­front for ex-Chi­na rights to Han­soh Phar­ma's an­ti­body-drug con­ju­gate

Last year
Deals

French biotech Abi­vax makes Nas­daq de­but, aim­ing to raise $236M to get PhI­II da­ta in IBD

Last year
Financing

Bio­gen CEO Chris Viehbach­er: Im­munol­o­gy is a nat­ur­al fit at biotech, calls for 'rein­ven­tion'

Last year
People

Keytru­da's cer­vi­cal can­cer da­ta; Ar­cutis’ of­fer­ing; Alaya.bio an­nounces a CAR-T deal

Last year
News Briefing

Up­dat­ed: Am­gen spot­lights new ef­fi­ca­cy, safe­ty da­ta of mid-phase tar­latam­ab tri­al in hard-to-treat can­cer: #ES­MO23

Last year
R&D

J&J un­veils PhI­Ia da­ta of oral an­tivi­ral for dengue fever pre­ven­tion

Last year
R&D

#ES­MO23 dis­patch: What to know about the HER3 ADC that got Mer­ck to pay $2B cash

Last year
Deals

Co-found­ed by David Bak­er, Vilya rings in a per­ma­nent CEO; Al­lo­gene names Er­ic Schmidt's CFO suc­ces­sor

Last year
Peer Review

Mer­ck dou­bles down on AD­Cs with $4B up­front to Dai­ichi Sankyo, go­ing for ‘same in­ten­si­ty’ as megablock­buster ...

Last year
Deals

Q&A: Joe Jimenez talks about sal­vaging ‘stuck’ drugs and why a sub­stance abuse treat­ment could be worth bil­lions ...

Last year
People

Sam­sung's bi­o­log­ics plant in South Ko­rea re­ceives Form 483 over da­ta in­tegri­ty, oth­er ob­ser­va­tions

Last year
FDA+
Manufacturing

Bris­tol My­ers un­corks pos­i­tive PhI­II read­out for sub­cu­ta­neous Op­di­vo

Last year
R&D
Pharma

Risk-ben­e­fit de­ter­mi­na­tions: FDA fi­nal­izes long-await­ed guid­ance for drug­mak­ers

Last year
Pharma
FDA+

Eu­ro­pean court rules Te­va, Cephalon must pay $60M fine for re­verse pay­ment scheme af­ter failed ap­peal

Last year
Pharma
Law

PTC to sell roy­al­ties on block­buster SMA drug Evrys­di for up to $1.5B

Last year
Deals
Pharma

Mer­ck slams 'dra­con­ian penalties' en­forced un­der IRA in new court fil­ing

Last year
Pharma

Bio­con slammed with OAI; Hong Kong looks to WuXi for ADC abil­i­ties; Tan­vex Phar­ma launch­es CD­MO ser­vices 

Last year
Manufacturing

Up­dat­ed: Flag­ship merges its trou­bled cir­cu­lar RNA com­pa­ny Laronde with nanopar­ti­cle start­up Sen­da

Last year
Startups

Lon­za’s mod­est fore­cast for cell and gene ther­a­pies points to un­cer­tain­ty about sec­tor's fu­ture

Last year
Manufacturing

Up­dat­ed: J&J builds out glob­al man­u­fac­tur­ing ca­pac­i­ty for CAR-T Carvyk­ti

Last year
Cell/Gene Tx
Manufacturing

Beam cuts 20% of staff, looks to part­ner on base-edit­ed CAR-T one month af­ter dos­ing first pa­tient

Last year
R&D
Cell/Gene Tx

Chan Zucker­berg’s new cen­ter in New York; En­deav­or buys rights to ADC; Basilea ac­quires an­ti­fun­gal

Last year
News Briefing

Why a Wal­greens ex­ec is bet­ting that re­tail phar­ma­cies can be a force to change how health­care’s paid for and ...

Last year
Health Tech

Af­ter years of hype, the first AI-de­signed drugs fall short in the clin­ic

Last year
AI
In Focus
First page Previous page 260261262263264265266 Next page Last page
A service from the Financial Times